| dc.description.abstract | Metformin, a well-known medication for type 2 diabetes, has demonstrated promise in postponing or averting the disease's beginning in high-risk patients. The first line of treatment for type 2 diabetic mellitus is biguanides like metformin. They function well both on their own and in combination with other medications that decrease blood sugar. For T2DM control, aggressive treatment is required to fulfill targets for cardiovascular risk factors and blood sugar levels. In this context, in addition to its antihyperglycemic properties, metformin—an established and widely used first-line medication—stands out for its capacity to ameliorate endothelial dysfunction, hemostasis and oxidative stress, insulin resistance, lipid profiles, and fat redistribution. Its mode of action involves decreasing insulin resistance, raising insulin sensitivity, and lowering the quantity of glucose the liver produces. The medication is useful in lowering blood glucose levels without raising the risk of hypoglycemia, according to a large body of research. It is generally highly received, reasonably priced, and has little side effects. Despite metformin's therapy is widely used and effective, there are still significant drawbacks and difficulties with it, including gastrointestinal side effects, individual differences in response, and issues with using it in particular patient populations. With significant advantages in glycemic control and other areas, one of the cornerstones of type 2 diabetes treatment remains to be metformin. It's vital position in the arsenal against Type 2 Diabetes and associated problems is reaffirmed by ongoing research efforts that uncover its varied therapeutic potential and enhance its clinical efficacy. Diabetes, metformin, glucose, insulin, biguanides, hypoglycemia. | en_US |
